Robert E. Lewis

This study identifies KSR1 as a critical regulator of SCLC tumor initiation and cisplatin resistance, showing that its disruption enhances cisplatin toxicity and reduces tumor-initiating cells.

This study shows that SOS1 inhibition with BI-3406 enhances G12C inhibitor efficacy and delays resistance in lung adenocarcinoma by targeting resistance mechanisms and drug-tolerant persister cells.

This study investigates the role of Ksr2 in bone health, finding it negatively regulates femoral bone mass and influences adipocyte differentiation over osteoblasts in the bone marrow.